Vaccines Articles
Scientists at Georgia Institute ofTechnology have developed a needle-free vaccine against measles.
Results from a human trial of GlaxoSmithKline’s Ebola vaccine show it is safe and generates an immune response.
In response to the national measles outbreak, the American Academy of Pediatrics has released updated measles guidelines on its website.
A recent study found no link between the measles vaccine and autism.
GlaxoSmithKline has developed a new shingles vaccine that is 97 percent effective in adults ages 50 years to 70 years.
Recent research has found a new approach to stimulate the skin immune response to fight various pathogens with an easy-to-use needle-free vaccine.
At the end of February, the Centers forDisease Control and Prevention (CDC)reported that the 2014-15 seasonal influenza vaccine was just 18 percent effective against the dominant strain of flu.
An analysis of 67 research studies published in the July 1 edition of Pediatrics has found that serious complications related to vaccines are very rare, and there is no evidence that immunizations cause autism.
bioCSL has announced the donation of more than 700,000 doses of its influenza vaccine to the Partnership for Influenza Vaccine Introduction.
The Advisory Committee on Immunization Practices voted 15 to 0 to recommend a preference for the inhaled live attenuated influenza vaccine, FluMist Quadrivalent, for healthy children ages 2 years through 8 years.
The U.S. Food and Drug Administration (FDA) has approved PharmaJet Inc.’s Stratis 0.5mL Needle-Free Jet Injector for delivery of bioCSL Inc.’s AFLURIA influenza vaccine for individuals ages 18 to 64 years.
The National Institutes of Health began human testing of an ebola vaccine in a Phase I clinical trial in September.
